| Financier | Commitments |
|---|---|
| Asian Infrastructure Investment Bank | 250.00 |
| Borrower/Recipient | 474.00 |
| Indonesia Australia Bank Umbrella Fund | 9.90 |
| International Bank for Reconstruction and Development | 750.00 |
Indonesia: Emergency Response to COVID19
Abstract*
The objective of the Emergency Response to COVID-19 (Coronavirus) Program for Indonesia is to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness. The Program will focus on 4 results areas. Results Area 1 will address hospital and health system readiness and systemic improvements in the quality of care. The Program will support the expanded network of Ministry of Health (MOH)-owned... Show More
Development Objective
To prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness in Indonesia.
Key Details
Project Details
P173843
Closed
Pandu Harimurti , Somil Nagpal
Republic of Indonesia
April 6, 2020
(as of board presentation)
May 22, 2020
July 8, 2020
US$ 1483.90 million
Ministry of Health
2020
US$ 1009.90 million
N/A
Not Applicable
June 30, 2024
BANK APPROVED
March 4, 2024
Finances
Financing Plan (US$ Millions)
Total Project Financing (US$ Millions)
| Product Line | IBRD/IDA |
|---|---|
| IBRD Commitment | 750.00 |
| IDA Commitment | N/A |
| IBRD + IDA Commitment | 750.00 |
| Lending Instrument | |
|---|---|
| Grant Amount | 259.90 |
| Total Project Cost** | 1483.90 |
Summary Status of World Bank Financing (US$ Millions) as of March 31, 2025
No data available.
| Period | Financier | Transaction Type | Amount (US$) |
|---|---|---|---|
| Sep 16, 2020 | IBRD-91220 | Loan Disb | 62,500,000.00 |
| Aug 24, 2020 | IBRD-91220 | Fee Charges | 625,000.00 |
| Mar 15, 2021 | IBRD-91220 | Int Charges | 652,666.70 |
| Dec 2, 2020 | IBRD-91220 | Loan Disb | 150,000,000.00 |
| Jun 22, 2021 | IBRD-91220 | Loan Disb | 37,500,000.00 |
| Oct 15, 2021 | IBRD-92630 | Fee Charges | 1,250,000.00 |
| Sep 15, 2021 | IBRD-91220 | Int Charges | 951,468.75 |
| Mar 15, 2022 | IBRD-91220 | Int Charges | 980,416.70 |
| Jan 25, 2022 | IBRD-92630 | Loan Disb | 304,216,288.00 |
| Jan 20, 2022 | IBRD-92630 | Loan Disb | 94,500,000.00 |
| Aug 1, 2022 | IBRD-92630 | Int Charges | 70,709.47 |
| Aug 1, 2022 | IBRD-92630 | Int Charges | 2,405,702.00 |
| Dec 19, 2022 | IBRD-92630 | Loan Disb | 18,550,000.00 |
| Sep 28, 2022 | IBRD-92630 | Loan Disb | 82,733,696.00 |
| Sep 15, 2022 | IBRD-91220 | Int Charges | 2,218,492.00 |
| Feb 1, 2023 | IBRD-92630 | Int Charges | 254.11 |
| Feb 1, 2023 | IBRD-92630 | Int Charges | 10,059,557.00 |
| Mar 15, 2023 | IBRD-91220 | Int Charges | 6,181,772.00 |
| Mar 15, 2023 | IBRD-91220 | Int Charges | 285,148.97 |
| Feb 1, 2023 | IBRD-92630 | Int Charges | 442,460.88 |
| Sep 15, 2023 | IBRD-91220 | Int Charges | 95,484.38 |
| Sep 15, 2023 | IBRD-91220 | Int Charges | 7,168,762.50 |
| Aug 1, 2023 | IBRD-92630 | Int Charges | 5,590.41 |
| Aug 1, 2023 | IBRD-92630 | Int Charges | 525,847.25 |
| Aug 1, 2023 | IBRD-92630 | Int Charges | 13,773,139.00 |
| Aug 1, 2024 | IBRD-92630 | Int Charges | 103,440.34 |
| Aug 1, 2024 | IBRD-92630 | Int Charges | 16,149,601.00 |
| Feb 1, 2024 | IBRD-92630 | Int Charges | 116,565.57 |
| Feb 1, 2024 | IBRD-92630 | Int Charges | 16,093,344.00 |
| Mar 15, 2024 | IBRD-91220 | Int Charges | 128,268.77 |
| Mar 15, 2024 | IBRD-91220 | Int Charges | 7,976,461.50 |
| May 22, 2020 | IBRD-91220 | Loan Commitment | 250,000,000.00 |
| Jun 17, 2021 | IBRD-92630 | Loan Commitment | 500,000,000.00 |
Ratings
Results Framework
PROJECT DEVELOPMENT OBJECTIVE INDICATORS
| INDICATOR | BASELINE | CURRENT | TARGET |
|---|
Reduced service readiness gap in treating severe respiratory illness patients (as measured by the available number of intensive care beds equipped as per national protocol) Value 0.00 35908.00 6000.00 Date April 1, 2020 December 29, 2023 June 30, 2024 Comment Strengthened laboratory capacity (measured as total capacity for quality assured tests per day) Value 3000.00 582828.00 90000.00 Date April 1, 2020 February 15, 2022 June 30, 2024 Comment Percentage of population vaccinated, which is included in the priority population targets defined in national plan (by gender) Value 1.73 24.00 48.02 Date May 3, 2021 June 1, 2023 June 30, 2024 Comment Improved reporting and surveillance system (measured as the availability of an improved surveillance system that incorporates lessons from the COVID-19 response experience) Value None Improved integrated surveillance system available. Improved surveillance system available. Date April 1, 2020 June 2, 2023 June 30, 2024 Comment Enhanced community engagement and communication (as measured by the number of interactions with the COVID-19 phone line) Value 0.00 103462.00 25000.00 Date April 1, 2020 September 30, 2022 June 30, 2024 Comment
INTERMEDIATE RESULTS INDICATORS
| INDICATOR | BASELINE | CURRENT | TARGET |
|---|
MOH supports the creation of a multi-sectoral coordination mechanism for COVID-19 response Value No Yes Yes Date March 1, 2020 October 31, 2022 October 31, 2021 Comment Number of beds temporarily converted for patient isolation and/or low intensity medical care Value 0.00 107966.00 6011.00 Date April 1, 2020 October 31, 2022 June 30, 2023 Comment A surveillance mechanism for community-based reporting of outbreaks and new illnesses among humans and animals is functional Value No Yes Yes Date April 1, 2020 October 31, 2022 October 31, 2021 Comment Cumulative number of website visitors to the COVID-19 communication portal set up by the Government of Indonesia Value 5000.00 4003700.00 750000.00 Date April 1, 2020 October 31, 2022 June 30, 2023 Comment Number of COVID-19 cases successfully treated, disaggregated by sex Value 0.00 6012818.00 1800000.00 Date March 1, 2020 October 31, 2022 June 30, 2023 Comment Number of functional locations with remote temperature monitoring system Value 0.00 2650.00 2000.00 Date December 31, 2020 June 2, 2023 June 30, 2023 Comment Cumulative number of cases MOH counters COVID-19 vaccine related misinformation and posts on its website Value 25.00 1361.00 532.00 Date April 1, 2020 October 31, 2022 June 30, 2023 Comment Infection prevention and clinical management protocols developed and disseminated to all non-referral facilities Value No Yes Yes Date April 1, 2020 October 31, 2022 October 31, 2021 Comment Pharmacovigilance system to monitor any adverse events related to COVID-19 vaccines is functional and producing reports. Value A pharmacovigilance system is being established. A pharmacovigilance system has been established an A pharmacovigilance system is fully functional and Date April 30, 2021 June 2, 2023 December 31, 2022 Comment Number of simulation exercises undertaken as per updated national pandemic preparedness plan Value 0.00 2.00 2.00 Date April 1, 2020 June 2, 2023 June 30, 2023 Comment Maintaining essential non COVID-19 services (% decline of number of completed fourth ANC services delivered in the previous quarteras a proportion to the corresponding quarter in 2019) Value 88.50% 88.7 At least 81.25% Date December 31, 2020 October 31, 2022 March 31, 2023 Comment MOH involved in the multi sector effort to monitor and counter measure misinformation about COVID-19 Vaccines Value No Yes Yes Date February 26, 2021 June 2, 2023 March 31, 2022 Comment Concrete measures to support and compensate health professionals for added COVID-19 related workload and risk are implemented Value No Yes Yes Date April 1, 2020 June 2, 2023 October 31, 2021 Comment Cumulative number of COVID-19 suspect cases tested by PCR or rapid molecular testing, disaggregated by sex Value 10000.00 68811162.00 7000000.00 Date April 1, 2020 June 2, 2023 June 30, 2023 Comment